Anti-Human PD-1 (Tislelizumab)

Anti-Human PD-1 (Tislelizumab)

Product No.: P800

- -
- -
Product No.P800
Clone
BGB-A317
Target
PD-1
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Anti-PD-1, PDCD1, CD279
Isotype
Human IgG4κ
Applications
ELISA
,
FA
,
FC
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Recommended Isotype Controls
Immunogen
Human PD-1
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA,
WB
Additional Applications Reported In Literature ?
FA,
ELISA Cap,
FC,
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Tislelizumab activity is directed against human PD-1 (CD274).
Antigen Distribution
PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells and is also retained in the intracellular compartments of regulatory T cells (Tregs).
Background
Programmed cell death 1 (PD-1) is a transmembrane protein in the Ig superfamily1,2 that acts as an immune checkpoint receptor3, a T cell inhibitory receptor, plays critical roles in peripheral tolerance induction, autoimmune disease prevention, macrophage phagocytosis, tumor cell glycolysis, and dendritic cell survival2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2. Programmed cell death 1 ligand 1 (PD-L1; CD274; B7H1) and programmed cell death 1 ligand 2 (PD-L2; CD273; B7DC) are ligands1.

Tislelizumab was developed by BeiGene as an immunotherapeutic for hematological cancers and advanced solid tumors4. Tislelizumab is a humanized mouse monoclonal antibody designed as a synthetic protein fusion of the 317-4B6 heavy chain VH fragment with human γ4 chain clone mut10 effector/constant domain fragment (disulfide with anti-human PD-1) and synthetic clone 317-4B6 light chain VL fragment with human κ chain constant region fragment, dimer4,5.

Tislelizumab binds to PD-1 with high specificity and affinity using the critical epitopes Gln75, Thr76, Asp77 and Arg86, blocking PD-1 and preventing ligand binding4. The epitope is located on the CC’ loop of the front β sheet face of PD-1 and causes stereospecific hindrance to PD-L1 binding6. Unlike other IgG4 anti-PD-1 blocking antibodies, the S228P mutation known to bind to Fc-γ receptor 1 (FcγRI) and induce antibody-dependent cellular phagocytosis of T cells is not present4 and several mutations in the Fc-hinge region render tislelizumab unable to bind to FcγRs generally6. Consequently, tislelizumab has low affinity for FcγRI and baseline antibody-dependent cellular phagocytosis relative to control antibodies4. Additionally, FcR-mediated effects such as antibody-dependent cell-mediated cytotoxicity or compliment-dependent cytotoxicity are not observed4,6.

Antigen Details

Ligand/Receptor
PD-1, CD279
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer
.
Immuno-Oncology
.
Immunology

References & Citations

1. Matsumoto K, Inoue H, Nakano T, et al. J Immunol. 172(4):2530-2541. 2004.
2. Zhao Y, Harrison DL, Song Y, et al. Cell Rep. 24(2):379-390.e6. 2018.
3. Pardoll DM. Nat Rev Cancer. 12(4):252-264. 2012.
4. Lee A, Keam SJ. Drugs. 80(6):617-624. 2020.
5. https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/tislelizumab.pdf
6. Zhang L, Geng Z, Hao B, et al. Cancer Control. 29:10732748221111296. 2022.
7. Zhang T, Song X, Xu L, et al. Cancer Immunol Immunother. 67(7):1079–90. 2018.
8. Zhang T, Song J, Li Y, et al. Cancer Research Conference: 107th AACR Annual Meeting 2016;76(Suppl 14).
9. Desai J, Deva S, Lee JS, et al. J Immunother Cancer. 8(1):e000453. 2020.
10. Song Y, Gao Q, Zhang H, et al. Leukemia. 34(2):533-542. 2020.
11. Hong Y, Feng Y, Sun H, et al. FEBS Open Bio. 11(3):782-792. 2021.
Indirect Elisa Protocol
FA
Flow Cytometry
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.